Limits...
Phellinus linteus Extract Augments the Immune Response in Mitomycin C-Induced Immunodeficient Mice.

Matsuba S, Matsuno H, Sakuma M, Komatsu Y - Evid Based Complement Alternat Med (2008)

Bottom Line: MMC groups were given MMC (1 mg/kg/day) intraperitoneally for 6 days with PLW administration.The number of PFC per 10(6) spleen cells increased significantly in the PLW (2 g/kg/day) group when compared with the MMC-control (P < 0.05) while populations of IFNgamma- and IL-4-producing T lymphocytes decreased by MMC treatment.Our results indicated that PLW augments the immune response of the spleen in MMC-induced immunodeficient mice.

View Article: PubMed Central - PubMed

Affiliation: Kanazawa Medical University, Department of Fundamental Research for CAM, Uchinada, Ishikawa prefecture and Sun R&D Institute for Natural Medicines Co, Inc., Tokyo, Japan.

ABSTRACT
Phellinus linteus is a fungus distributed throughout Japan, Korea and China. Boiled water-soluble extracts from P. linteus (PLW) have shown anti-tumor and immunomodulatory properties in experiments done by intraperitoneal treatment, or in in vitro cell cultures. This is the first investigation on how oral administration of PLW influences immune responses. Here, we established immunodeficient mice by mitomycin C (MMC) and then researched how PLW influenced plaque-forming cell (PFC) production and populations of cytokine [interferon- (IFNgamma-) and interleukin-4 (IL-4)]-producing T lymphocytes. PLW samples were administered orally for 19 days (1, 2 or 4 g/kg/day). PFC assay was followed using Jerne's method. IFN- and IL-4-producing T lymphocyte populations were measured by flow-activated cell sorter (FACS). These assays were conducted the day after the last oral administration. MMC groups were given MMC (1 mg/kg/day) intraperitoneally for 6 days with PLW administration. The number of PFC per 10(6) spleen cells increased significantly in the PLW (2 g/kg/day) group when compared with the MMC-control (P < 0.05) while populations of IFNgamma- and IL-4-producing T lymphocytes decreased by MMC treatment. However, the PLW group tended to increase more than the MMC-control. Our results indicated that PLW augments the immune response of the spleen in MMC-induced immunodeficient mice.

No MeSH data available.


Related in: MedlinePlus

Recovered period from immunodeficient condition by Mitomycin C treatments (i.p., 1 mg/kg/day, 6 days) on the weight of spleen (mg) and the number of PFC per 106 spleen cells in normal mice. Each value represents the mean ± SD (n = 7); **P < 0.005 versus control.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC2249738&req=5

Figure 2: Recovered period from immunodeficient condition by Mitomycin C treatments (i.p., 1 mg/kg/day, 6 days) on the weight of spleen (mg) and the number of PFC per 106 spleen cells in normal mice. Each value represents the mean ± SD (n = 7); **P < 0.005 versus control.

Mentions: In researching augmentation of the immune response to PLW administration in immunodeficient mice, we investigated the recovery period from MMC-initiated immunodeficiency. Results showed that PFC were not produced 1 week after the last treatment. However, production gradually recovered after 2 weeks (Fig. 2). The numbers of PFC per 106 spleen cells in each period were 88 ± 27 (2 weeks), 261 ± 145 (3 weeks), 371 ± 144 (4 weeks), showing significant differences at 1 and 2 weeks against the control (P < 0.005). Spleen weight at 1 week was lower than that of the control (P < 0.005). There was no significant difference between the populations of CD19-positive cells in the spleen (Table 1), suggesting that MMC treatment only slightly altered the CD19-positive cell population. Since recovery from immunodeficiency began 2 weeks after the last MMC treatment, we decided to assay PFC and flow-activated cell sorter (FACS) at that time.Table 1.


Phellinus linteus Extract Augments the Immune Response in Mitomycin C-Induced Immunodeficient Mice.

Matsuba S, Matsuno H, Sakuma M, Komatsu Y - Evid Based Complement Alternat Med (2008)

Recovered period from immunodeficient condition by Mitomycin C treatments (i.p., 1 mg/kg/day, 6 days) on the weight of spleen (mg) and the number of PFC per 106 spleen cells in normal mice. Each value represents the mean ± SD (n = 7); **P < 0.005 versus control.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC2249738&req=5

Figure 2: Recovered period from immunodeficient condition by Mitomycin C treatments (i.p., 1 mg/kg/day, 6 days) on the weight of spleen (mg) and the number of PFC per 106 spleen cells in normal mice. Each value represents the mean ± SD (n = 7); **P < 0.005 versus control.
Mentions: In researching augmentation of the immune response to PLW administration in immunodeficient mice, we investigated the recovery period from MMC-initiated immunodeficiency. Results showed that PFC were not produced 1 week after the last treatment. However, production gradually recovered after 2 weeks (Fig. 2). The numbers of PFC per 106 spleen cells in each period were 88 ± 27 (2 weeks), 261 ± 145 (3 weeks), 371 ± 144 (4 weeks), showing significant differences at 1 and 2 weeks against the control (P < 0.005). Spleen weight at 1 week was lower than that of the control (P < 0.005). There was no significant difference between the populations of CD19-positive cells in the spleen (Table 1), suggesting that MMC treatment only slightly altered the CD19-positive cell population. Since recovery from immunodeficiency began 2 weeks after the last MMC treatment, we decided to assay PFC and flow-activated cell sorter (FACS) at that time.Table 1.

Bottom Line: MMC groups were given MMC (1 mg/kg/day) intraperitoneally for 6 days with PLW administration.The number of PFC per 10(6) spleen cells increased significantly in the PLW (2 g/kg/day) group when compared with the MMC-control (P < 0.05) while populations of IFNgamma- and IL-4-producing T lymphocytes decreased by MMC treatment.Our results indicated that PLW augments the immune response of the spleen in MMC-induced immunodeficient mice.

View Article: PubMed Central - PubMed

Affiliation: Kanazawa Medical University, Department of Fundamental Research for CAM, Uchinada, Ishikawa prefecture and Sun R&D Institute for Natural Medicines Co, Inc., Tokyo, Japan.

ABSTRACT
Phellinus linteus is a fungus distributed throughout Japan, Korea and China. Boiled water-soluble extracts from P. linteus (PLW) have shown anti-tumor and immunomodulatory properties in experiments done by intraperitoneal treatment, or in in vitro cell cultures. This is the first investigation on how oral administration of PLW influences immune responses. Here, we established immunodeficient mice by mitomycin C (MMC) and then researched how PLW influenced plaque-forming cell (PFC) production and populations of cytokine [interferon- (IFNgamma-) and interleukin-4 (IL-4)]-producing T lymphocytes. PLW samples were administered orally for 19 days (1, 2 or 4 g/kg/day). PFC assay was followed using Jerne's method. IFN- and IL-4-producing T lymphocyte populations were measured by flow-activated cell sorter (FACS). These assays were conducted the day after the last oral administration. MMC groups were given MMC (1 mg/kg/day) intraperitoneally for 6 days with PLW administration. The number of PFC per 10(6) spleen cells increased significantly in the PLW (2 g/kg/day) group when compared with the MMC-control (P < 0.05) while populations of IFNgamma- and IL-4-producing T lymphocytes decreased by MMC treatment. However, the PLW group tended to increase more than the MMC-control. Our results indicated that PLW augments the immune response of the spleen in MMC-induced immunodeficient mice.

No MeSH data available.


Related in: MedlinePlus